List of Excipients in Branded Drug FERRIC CARBOXYMALTOSE

Generic Drugs Containing FERRIC CARBOXYMALTOSE

Company	Ingredient	NDC	Excipient
Mylan Institutional LLC	ferric carboxymaltose	67457-797	HYDROCHLORIC ACID
Mylan Institutional LLC	ferric carboxymaltose	67457-797	SODIUM HYDROXIDE
Mylan Institutional LLC	ferric carboxymaltose	67457-797	WATER
Mylan Institutional LLC	ferric carboxymaltose	72078-060	HYDROCHLORIC ACID
Mylan Institutional LLC	ferric carboxymaltose	72078-060	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in FERRIC CARBOXYMALTOSE?

# Of NDCs	Excipient
2	HYDROCHLORIC ACID
2	SODIUM HYDROXIDE
2	WATER

Ferric Carboxymaltose Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Ferric carboxymaltose is an established intravenous iron complex marketed primarily as Injectafer in the United States and Ferinject in many international markets. The core commercial opportunity is not a conventional excipient substitution. It is the development of differentiated, ready-to-use iron-carbohydrate formulations with improved stability, administration efficiency, container performance, safety monitoring, and regulatory positioning.

The active complex is technically difficult to replicate because ferric carboxymaltose is a polynuclear iron(III)-oxyhydroxide complex stabilized by carboxymaltose. Product development must control iron-core structure, carbohydrate molecular-weight distribution, labile iron, particle characteristics, osmolality, pH, impurities, and infusion-related performance. Excipients support these attributes but cannot be treated as independent formulation variables.

What is ferric carboxymaltose and how is it commercialized?

Ferric carboxymaltose is a high-dose intravenous iron replacement product. It permits administration of up to 750 mg of iron per dose in many approved regimens, reducing the number of treatment visits compared with lower-dose intravenous iron products.

Attribute	Ferric carboxymaltose
Primary active ingredient	Iron(III)-carboxymaltose complex
Common brand names	Injectafer, Ferinject
Administration	Intravenous injection or infusion, depending on jurisdiction and presentation
Typical concentration	50 mg elemental iron/mL
Common vial presentations	10 mL and 15 mL, depending on market
Main therapeutic use	Iron-deficiency anemia and selected iron-deficiency conditions
Original U.S. approval	Injectafer, 2013
U.S. commercial parties	American Regent and CSL Vifor-related commercial interests
Principal formulation risk	Complex iron-carbohydrate equivalence and physicochemical comparability
Key safety issue	Hypophosphatemia, including clinically significant cases

The product is supplied as an aqueous, dark brown-to-black sterile solution. The formulation generally uses water for injection with sodium hydroxide and hydrochloric acid as pH-adjusting agents. The ferric carboxymaltose complex provides the principal colloidal and chemical functionality; the excipient system is intentionally limited. [1, 2]

What excipients are used in ferric carboxymaltose injections?

The standard excipient platform is minimal:

Component	Function	Commercial significance
Water for injection	Vehicle	Controls solubility, sterility, osmolality, and container compatibility
Sodium hydroxide	pH adjustment	Influences complex stability and injectable tolerability
Hydrochloric acid	pH adjustment	Provides final pH control and batch consistency
Carboxymaltose	Ligand and stabilizing carbohydrate within the active complex	Determines iron release, complex integrity, and product comparability

Injectafer labeling identifies water for injection, sodium hydroxide, and hydrochloric acid as inactive ingredients or formulation components. The carboxymaltose component is chemically integrated into the iron complex and is generally treated as part of the active pharmaceutical ingredient rather than as a conventional free excipient. [1]

Why are conventional excipient substitutions limited?

Ferric carboxymaltose is not a simple molecular solution. Its performance depends on a controlled iron-carbohydrate colloidal structure. Adding common excipients such as polysorbates, citrate, phosphate, amino acids, or chelators could alter:

• Iron release kinetics
• Labile iron concentration
• Transferrin interaction
• Macrophage uptake
• Osmolality
• Infusion tolerability
• Particle-size distribution
• Hypophosphatemia risk
• Long-term chemical stability

Phosphate-containing excipients are particularly unattractive because phosphate metabolism is already clinically relevant to ferric carboxymaltose treatment. The product has been associated with hypophosphatemia, and repeated dosing can create clinically meaningful phosphate depletion in susceptible patients. [1, 3]

What formulation patents protect ferric carboxymaltose products?

Ferric carboxymaltose protection has historically centered on the iron-carbohydrate complex, manufacturing process, molecular characterization, and therapeutic use rather than on a broad excipient platform.

Core patent categories

Patent category	Protected subject matter	Relevance to competitors
Composition patents	Iron oxyhydroxide-carbohydrate complexes and related structures	Can create the primary composition-of-matter barrier
Process patents	Preparation of iron cores, carbohydrate attachment, purification, and drying or concentration steps	May constrain manufacturing routes
Product-quality patents	Defined iron-to-carbohydrate ratios, molecular-weight profiles, viscosity, and stability	Supports differentiation and equivalence arguments
Formulation patents	Aqueous injectable compositions, concentration, pH, and administration formats	Can protect ready-to-use products
Method-of-use patents	Treatment of iron deficiency, chronic kidney disease, heart failure, or specific dosing schedules	Can affect generic labeling and litigation
Device and packaging patents	Vial, syringe, infusion, or administration systems	Usually secondary to active-complex protection

The relevant patent analysis must distinguish patents covering ferric carboxymaltose itself from patents covering a particular brand, indication, dosage regimen, or presentation. A competitor may avoid a formulation patent while still facing substantial technical barriers from the active-complex and manufacturing estate.

What is the Orange Book status of Injectafer?

Injectafer is approved under U.S. NDA 203565. Orange Book analysis should focus on listed patents, expiration dates, pediatric extensions, and whether any patent covers the proposed ANDA labeling or dosage regimen. FDA’s Orange Book is the controlling source for current listed-patent status. [4]

The commercial significance of Orange Book listings is narrower than the total patent estate:

1. An Orange Book-listed patent can support a Paragraph IV certification and patent litigation.
2. A non-listed process patent may still create manufacturing risk but generally does not block ANDA approval through the same mechanism.
3. A method-of-use patent may be avoidable through a skinny label if the relevant indication can be carved out.
4. A complex injectable product can face approval risk even after basic composition patents expire because FDA may require robust sameness and comparative characterization.

When does ferric carboxymaltose lose exclusivity?

The original U.S. regulatory exclusivity for Injectafer has expired. The principal commercial question is therefore the remaining enforceability of listed patents, later-issued patents, pediatric exclusivity, and the technical feasibility of an abbreviated or alternative approval pathway.

A patent expiry date alone does not establish immediate generic entry. Launch timing also depends on:

• ANDA or 505(b)(2) approval
• Paragraph IV litigation
• Regulatory hold or tentative approval
• Availability of non-infringing manufacturing technology
• Commercial-scale control of the iron-carbohydrate complex
• Hospital and specialty-pharmacy contracting
• Clinical concerns about hypophosphatemia

How difficult is a generic ferric carboxymaltose product to develop?

Ferric carboxymaltose is a complex injectable iron product, not a conventional small-molecule solution. The principal challenge is demonstrating that a proposed product has the same relevant quality and clinical performance characteristics as the reference product.

Technical comparability requirements

A competitor is likely to need extensive data on:

• Total iron content
• Iron oxidation state
• Iron-core size and morphology
• Carbohydrate identity and molecular-weight distribution
• Iron-to-carbohydrate ratio
• Labile iron
• Transferrin-binding behavior
• Reduction kinetics
• Particle-size distribution
• Viscosity and osmolality
• pH
• Free carbohydrate and inorganic impurities
• Residual solvents and metals
• Sterility and bacterial endotoxins
• Container-closure integrity
• In-use stability

The formulation may contain only a few excipients, but the active complex creates a large analytical burden. A product that matches elemental iron concentration while differing in iron release or carbohydrate distribution may not be viewed as clinically interchangeable.

ANDA versus 505(b)(2) strategy

Pathway	Strategic advantage	Principal risk
ANDA	Potentially lower clinical-development burden and substitutable generic positioning	High comparability burden for a complex iron-carbohydrate product
505(b)(2) NDA	Supports differentiated formulation, dosing, device, or clinical-use claims	Higher cost and possible need for clinical bridging
Full NDA	Allows a new iron complex or material change	Longest development timeline and highest evidence burden
Foreign reference or hybrid pathway	May support selected international markets	Reference-product and local regulatory requirements vary

A company seeking to preserve a narrow excipient platform while changing the complex itself may have a stronger 505(b)(2) case than an ANDA case. Conversely, a product that closely matches Injectafer’s complex and excipient system may pursue an ANDA if FDA accepts the analytical and clinical comparability package.

What excipient opportunities exist for ferric carboxymaltose?

The highest-value opportunities involve controlled performance improvements, not adding excipients for their own sake.

1. pH and buffering optimization

The commercial objective is a stable injectable product with a narrow pH range and limited risk of iron precipitation or altered complex structure. A buffered formulation could improve batch robustness, but buffer selection is constrained by compatibility with iron and the risk of changing iron release.

Potential development areas include:

• Low-capacity buffering
• Improved pH control during shelf life
• Reduced pH drift after vial opening
• Lower interaction with elastomeric stoppers
• Compatibility with infusion fluids where permitted

A buffer system would require comparative testing for free iron, oxidative degradation, precipitation, osmolality, and infusion tolerability.

2. Osmolality and infusion tolerability

Ferric carboxymaltose is administered intravenously at high iron doses. A formulation with optimized osmolality and reduced injection discomfort could support outpatient infusion centers, hospital protocols, and home-infusion models where permitted.

Potential value propositions include:

• Lower infusion-related discomfort
• Reduced need for dilution
• More consistent administration through peripheral access
• Reduced nursing time
• Compatibility with automated infusion devices

The opportunity is commercially meaningful because administration time affects total treatment cost even when the acquisition price is similar.

3. Ready-to-use presentations

A ready-to-use formulation can reduce preparation steps and compounding error risk. Possible formats include:

• Pre-filled syringes
• Ready-to-administer bags
• Single-dose vials with optimized fill volumes
• Small-volume high-concentration presentations
• Device-compatible cartridges

Packaging and device patents may provide more durable protection than a basic excipient change, particularly if the presentation reduces preparation time or supports ambulatory treatment.

4. Container-closure systems

Iron-containing formulations can interact with packaging materials and may expose products to leachables, adsorption, or particulate risk. Commercial opportunities include:

• Low-extractable elastomeric closures
• Improved glass or polymer containers
• Prefilled delivery systems
• Light-protective packaging
• Container systems with reduced residual volume

Container changes can support a 505(b)(2) strategy if they produce a clinically or operationally relevant advantage.

5. Stability-enhancing excipient systems

The product must remain chemically and physically stable without promoting iron release. Stabilization efforts may examine:

• Carbohydrate concentration
• Ionic strength
• Trace-metal control
• Oxygen exposure
• Headspace management
• Chelation risk
• Antioxidant compatibility

Common antioxidants or chelators should not be assumed to be suitable. They can alter iron redox chemistry and may introduce new safety or regulatory issues.

6. Reduced hypophosphatemia positioning

Hypophosphatemia is a major product-differentiation opportunity, but an excipient-only solution is unlikely to be sufficient. The adverse effect is linked primarily to ferric carboxymaltose pharmacology and fibroblast growth factor 23 biology rather than to a conventional excipient effect. [3]

A credible lower-risk product would likely require:

• Modified iron-carbohydrate release characteristics
• Comparative phosphate data
• Repeat-dose studies
• Monitoring of intact and C-terminal FGF23
• Evidence in high-risk populations
• A defined clinical advantage over Injectafer and other IV iron products

An excipient change could support the product but is unlikely to establish the claim independently.

Which companies compete with ferric carboxymaltose?

Ferric carboxymaltose competes with other intravenous iron complexes, oral iron, and newer oral iron-replacement products.

Product	Active complex	Main commercial distinction
Injectafer/Ferinject	Ferric carboxymaltose	High-dose IV iron and broad use across iron-deficiency settings
Venofer	Iron sucrose	Established hospital and dialysis use, usually requiring multiple doses
Feraheme	Ferumoxytol	High-dose IV iron with a differentiated administration schedule
Monoferric	Ferric derisomaltose	High-dose IV iron and competing iron-carbohydrate profile
INFeD	Iron dextran	Older product with broad iron replacement use
Oral iron products	Ferrous salts and newer oral agents	Lower acquisition cost but slower correction and tolerability limitations

The main commercial contest is between high-dose IV iron products. A new ferric carboxymaltose product must compete on total treatment cost, infusion-center throughput, phosphate safety, supply reliability, contracting, and evidence in heart failure or chronic kidney disease.

What regulatory status and clinical issues affect commercial opportunity?

FDA-approved use has expanded beyond the original adult iron-deficiency anemia population. Current labeling must be reviewed for the exact indications, age groups, dosing schedules, contraindications, warnings, and administration requirements. [1]

Key regulatory issues include:

• Hypersensitivity and anaphylactoid reactions
• Hypophosphatemia
• Hypertension after administration
• Iron overload
• Laboratory interference
• Pediatric dosing and safety
• Chronic kidney disease populations
• Heart-failure populations
• Repeat-dose exposure
• Dilution and infusion instructions

A differentiated product with a new administration device, altered concentration, or modified dosing regimen may require a 505(b)(2) submission even if the iron complex is closely related to the reference product.

What generic entry risks exist for Injectafer?

Generic entry risk is moderate to high from a technical perspective and depends on patent status from a legal perspective.

Near-term entry scenarios

Scenario	Likely market effect
No approved equivalent	Brand maintains price and contracting power
First complex injectable entrant	Price erosion may be limited initially, with hospital formulary pressure
Multiple approved entrants	Greater discounting and potential substitution
505(b)(2) differentiated entrant	Limited direct substitution but stronger clinical-positioning opportunity
Device-based entrant	May preserve pricing through workflow and administration advantages

Hospitals and integrated delivery networks may adopt a lower-priced product if it has reliable supply, comparable administration, and acceptable phosphate safety. Specialty and office-based infusion channels may prioritize dosing convenience and reimbursement economics.

How strong is the ferric carboxymaltose patent estate?

The estate is stronger technically than a simple excipient patent portfolio because it can cover the active complex, manufacturing process, product quality, and clinical use. Its commercial strength is reduced when:

• Core composition patents have expired
• Method-of-use claims can be carved out
• Manufacturing routes can be redesigned
• The competitor can demonstrate analytical comparability
• The reference product has no remaining regulatory exclusivity
• Hospital customers treat the products as clinically interchangeable

The most defensible new IP is likely to arise from:

• Narrowly defined complex attributes linked to performance
• Manufacturing controls that improve reproducibility
• Low-labile-iron compositions
• Improved stability and container systems
• Ready-to-use delivery formats
• Clinically validated lower-phosphate-risk formulations
• Specific patient populations and dosing regimens

What licensing and partnership opportunities exist?

Ferric carboxymaltose commercial development favors partnerships because the required capabilities span complex iron chemistry, sterile manufacturing, clinical development, and hospital commercialization.

Potential deal structures include:

1. Regional licensing of an Injectafer or Ferinject alternative.
2. Contract development and manufacturing for complex iron injectables.
3. Co-development of prefilled or ready-to-administer presentations.
4. Licensing of analytical methods for iron-carbohydrate comparability.
5. Hospital-channel partnerships based on administration-cost reduction.
6. Acquisition of manufacturing know-how covering iron-core and carbohydrate control.
7. Commercial partnerships for emerging markets where IV iron infrastructure is expanding.

A license should distinguish patent rights from know-how rights. For ferric carboxymaltose, process knowledge, analytical reference standards, impurity controls, and scale-up experience may be as important as the patent grant.

What is the revenue exposure and commercial upside?

Ferric carboxymaltose has substantial revenue exposure because it is a high-value IV iron product used in recurring-treatment settings. Revenue is concentrated in:

• United States Injectafer sales
• European Ferinject sales
• Chronic kidney disease
• Heart failure
• Gastrointestinal blood loss and malabsorption
• Women’s health and perioperative anemia
• Hospital and outpatient infusion centers

Commercial upside for a new product is highest when it can demonstrate one of four measurable benefits:

Benefit	Buyer impact
Fewer treatment visits	Lower facility and labor cost
Faster administration	Higher infusion-center capacity
Lower hypophosphatemia risk	Reduced monitoring and clinical-management burden
Better supply or packaging	Lower operational risk

Price-only competition is less attractive because established IV iron products have contracting power and experienced distribution networks.

Key Takeaways

• Ferric carboxymaltose uses a deliberately limited excipient system centered on water for injection and pH adjustment.
• The carboxymaltose ligand is integrated into the active iron complex and drives much of the product’s quality and clinical behavior.
• Conventional excipient substitution has limited value unless it improves stability, tolerability, packaging, or administration.
• The strongest commercial opportunities are ready-to-use formats, container systems, low-labile-iron products, and formulations with validated safety advantages.
• Generic development is technically complex because elemental iron equivalence does not establish full product equivalence.
• Injectafer’s regulatory exclusivity has expired, but listed patents, process patents, and method-of-use claims remain relevant to launch planning.
• Hypophosphatemia is the most important clinical differentiation opportunity.
• A 505(b)(2) strategy may be more suitable than an ANDA for materially differentiated formulations or delivery systems.
• Manufacturing know-how and analytical comparability methods are major licensing assets.
• Competition is strongest from ferumoxytol, ferric derisomaltose, iron sucrose, and established oral iron products.

FAQs

Can ferric carboxymaltose be reformulated with a different buffer?

Yes, but the new buffer must be evaluated for iron release, colloidal stability, osmolality, degradation, container compatibility, and clinical tolerability. A buffer change may require a 505(b)(2) regulatory strategy.

Is ferric carboxymaltose a biologic or biosimilar product?

No. Ferric carboxymaltose is a non-biologic iron-carbohydrate complex. Competitors are generally evaluated through generic, hybrid, or new-drug pathways rather than the U.S. biosimilar pathway.

Can phosphate be used as an excipient in ferric carboxymaltose?

Phosphate is generally unattractive because ferric carboxymaltose treatment can cause hypophosphatemia. Phosphate-containing formulations would require careful evaluation of chemical compatibility and clinical phosphate effects.

What is the best patent strategy for a new ferric carboxymaltose product?

The strongest strategy combines composition or product-quality claims with manufacturing, stability, container, device, and clinically supported method-of-use claims. A single broad excipient patent is unlikely to provide durable protection.

Which ferric carboxymaltose presentation has the greatest commercial potential?

A high-concentration, ready-to-administer presentation with validated stability, low preparation burden, robust container compatibility, and a clinically credible phosphate-safety advantage has the strongest differentiation potential.

References

1. U.S. Food and Drug Administration. (2024). Injectafer (ferric carboxymaltose injection) prescribing information. American Regent, Inc.

2. European Medicines Agency. (2023). Ferinject: EPAR product information. European Medicines Agency.

3. Wolf, M., Chertow, G. M., Macdougall, I. C., Kaper, R., Krop, J., & Strauss, W. (2018). Randomized trial of intravenous iron-induced hypophosphatemia. Journal of Clinical Investigation, 128(3), 1387-1397.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.